WallStSmart
GRI

GRI Bio Inc.

NASDAQ: GRI · HEALTHCARE · BIOTECHNOLOGY

$2.26
-6.10% today

Updated 2026-06-05

Market cap
$3.98M
P/E ratio
0.06
P/S ratio
EPS (TTM)
$38.89
Dividend yield
52W range
$2 – $80
Volume
0.1M

GRI Bio Inc. (GRI) Financial statements

SEC filings — annual and quarterly data.

Cash flow — annual

Item20182019202020212022202320242025
Operating cash flow$-2.37M$-2.88M$-3.71M$-847000.00$-1.08M$-8.99M$-8.61M$-10.19M
Capital expenditures$2206.00$5.00$2000.00$0.00$3000.00$8000.00$0.00$3000.00
Depreciation$612.00$735.00$75000.00$73000.00$50000.00$57000.00$4000.00
Stock-based comp$0.00$25000.00$388000.00$148000.00$793000.00
Free cash flow$-2.37M$-2.88M$-3.71M$-847000.00$-1.09M$-9.00M$-8.61M$-10.19M
Investing cash flow$-2204.00$-2000.00$-3.84M$-3000.00$-8000.00
Financing cash flow$2.99M$6.09M$-4000.00$15.75M$1.01M$10.95M$11.83M
Dividends paid$3.45M$2.92M
Share repurchases
Debt repayment
Net change in cash

Frequently asked questions

How much free cash flow does GRI generate?

GRI produced $-10.19M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is GRI's balance sheet healthy?

GRI holds $8.23M in cash and equivalents against — in long-term debt, on $6.01M of shareholder equity. That debt is best read against the cash flow the business throws off each year.